Gilead Sciences Inc. / Triangle Pharmaceuticals Inc.

HIV-1 Infection

38K US cases/yr

Disease Overview

HIV-1 is a chronic retroviral infection requiring lifelong antiretroviral therapy. Modern combination regimens suppress viral replication and prevent progression to AIDS but rely on backbone nucleoside reverse transcriptase inhibitors (NRTIs) like tenofovir and emtricitabine that anchor most fixed-dose combinations.

Competitive Landscape

In late 2002, the HIV NRTI backbone landscape was dominated by GSK's Combivir (zidovudine/lamivudine) and Epivir (lamivudine), with BMS's Zerit (stavudine) and Videx (didanosine) declining due to mitochondrial toxicity. Gilead had launched Viread (tenofovir DF) in October 2001 and needed an NRTI partner to build a once-daily fixed-dose combination. Triangle's emtricitabine (FTC, Coviracil), licensed from Emory University in 1996, was at FDA filing stage with a once-daily profile and lamivudine-like resistance pattern. The $464M acquisition delivered exactly that: emtricitabine was approved as Emtriva in July 2003, and the tenofovir/emtricitabine fixed-dose Truvada launched in 2004, becoming the backbone of HIV therapy and later of Atripla, Stribild, Genvoya, Descovy, and PrEP. The deal is widely regarded as one of the most accretive in pharma history — Gilead transformed from a niche antiviral player into the dominant HIV franchise, with Truvada/Atripla generating multi-billion-dollar annual revenue and underwriting Gilead's later HCV and HIV mega-launches. The 2005 Royalty Pharma/Emory $525M royalty buyout further illustrated the asset's value.